These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15226096)

  • 1. Pravastatin potentiates the anticoagulant effects of low molecular weight heparin.
    Zimmer JE; Spillert CR; Puppala S; Zamecki K; Bhatt BA; Arora RR
    Thromb Res; 2004; 113(6):407-10. PubMed ID: 15226096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
    Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ; Shi XB; Yang JG; Hu DY
    Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E; Lakhani M; Marmur JD
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
    Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
    Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low molecular weight heparin on clot rate and activated clotting time: an in vitro study.
    Shi XB; Bai Y; Li J; Xiao J; Wang JQ; Zheng H
    Chin Med J (Engl); 2013; 126(18):3553-6. PubMed ID: 24034107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
    Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
    Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future alternatives to heparin: low-molecular-weight heparin and hirudin.
    Donayre CE; Ouriel K; Rhee RY; Shortell CK
    J Vasc Surg; 1992 Apr; 15(4):675-82. PubMed ID: 1313932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible mechanism of the synergistic effect of heparin and dihydroergotamine.
    Kakkar VV; Welzel D; Murray WJ; Malone P; Jones D
    Am J Surg; 1985 Oct; 150(4A):33-8. PubMed ID: 4051120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin.
    Gerotziafas GT; Dupont C; Spyropoulos AC; Hatmi M; Samama MM; Kiskinis D; Elalamy I
    Thromb Haemost; 2009 Jul; 102(1):42-8. PubMed ID: 19572066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD; Brandenburg VM; Lanzmich R; Floege J
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of unfractionated heparin and low molecular weight heparin on the clotting of platelet-reduced whole blood: an in-vitro study utilizing thromboelastography.
    Chung J; Stevic I; Gantioqui J; Atkinson H; Chan AKC; Chan HHW
    Blood Coagul Fibrinolysis; 2021 Jul; 32(5):305-311. PubMed ID: 34231501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.
    Katz BZ; Muhl L; Zwang E; Ilan N; Herishanu Y; Deutsch V; Naparstek E; Vlodavsky I; Preissner KT
    Thromb Haemost; 2007 Dec; 98(6):1193-9. PubMed ID: 18064313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting effects of low-molecular weight heparin and adrenocortical hormone on hemolysis of red cells in patients with paroxysmal nocturnal hemoglobinuria in vitro.
    Zhao M; Shao Z; Liu H; Cao Z; Tian P; Fu R; Shi J; He G; Bai J; Yang T
    Chin Med J (Engl); 2002 Nov; 115(11):1620-3. PubMed ID: 12609073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
    Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
    Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
    Konstantinidis K; Gerasimidis T; Verdy E; Elalamy I; Samama MM; Gerotziafas GT
    Thromb Haemost; 2007 Jan; 97(1):109-18. PubMed ID: 17200777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.